Opinion|Videos|December 20, 2024
Advances in Systemic Treatment Options for Prurigo Nodularis
Author(s)Shawn Kwatra, MD, FAAD
A panelist discusses how the treatment landscape for prurigo nodularis (PN) has evolved from primarily using topical therapies and off-label systemic medications to incorporating FDA-approved targeted biologics such as dupilumab and nemolizumab, which have demonstrated significant efficacy in reducing both the itchiness and nodular lesions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Priorto the FDA approval of 2 systemic treatment options for PN, what was your typical treatment approach for patients with PN? At what point would systemic therapy be considered for a patient?
- How has this treatment approach changed in recent years after the FDA approval of biologic systemic treatments for PN? In your opinion, what is the role in therapy for these agents?
- Briefly discuss the 2 agents that are currently FDA-approved for PN, including how they work to address itch and skin lesions, as well as efficacy and safety data.
- Dupilumab
- Nemolizumab
- Discuss other systemic therapies in the pipeline for the treatment of prurigo nodularis (eg, Janus kinase inhibitors).
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
5